Resources

Clinical Trials

Trial Spotlight

Clinical Research Study for Teens and other Adolescents with Hidradenitis Suppurativa


This is a research study evaluating the safety of an investigational drug as well as how it is processed in the body.

  • Age: 12-17
  • Severity: moderate to severe
  • Location: US
View Details

Clinical Trial Opportunities

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

AGE: 18+

Moderate to Severe

LOCATION: International

View Details

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

AGE: 12+

Moderate to Severe

LOCATION: International

View Details

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

AGE: 18+

ALL

LOCATION: US Only

View Details

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

AGE: 18+

Moderate to Severe

LOCATION: International

View Details

A Study With CIT-013 in HS Patients

AGE: 18+

II & III

LOCATION: International

View Details

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (TibuSHIELD)

AGE: 18+

II & III

LOCATION: International

View Details

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

AGE: 18+

ALL

LOCATION: US Only

View Details

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

AGE: 18+

Moderate to Severe

LOCATION: US Only

View Details

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

AGE: 18+

I & II

LOCATION: US Only

View Details

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

AGE: 12 -17

Moderate to Severe

LOCATION: US Onky

View Details

An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

AGE: 18+

Moderate to Severe

LOCATION: US Only

View Details

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

AGE: 18+

Moderate to Severe

LOCATION: US Only

View Details

A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa

AGE: 18+

All

LOCATION: US Only

View Details

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

AGE: 18+

Moderate to Severe

LOCATION: International

View Details

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

AGE: 18+

Moderate to Severe

LOCATION: International

View Details

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

AGE: 12+

I & II

LOCATION: International

View Details

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

AGE: 12+

I & II

LOCATION: International

View Details

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

AGE: 9 to 17

Moderate to Severe

LOCATION: International

View Details

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

AGE: 12+

I, II, III

LOCATION: US Only

View Details

Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

AGE: 12+

Moderate to Severe

LOCATION: International

View Details

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

AGE: 18-75

SEVERITY: Moderate to severe

LOCATION: US Only

View Details

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

AGE: 18+

SEVERITY: Moderate to severe

LOCATION: International

View Details

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) (CEDAR)

AGE: 18-80

SEVERITY: Moderate or severe

LOCATION: US Only

View Details

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

AGE: 18+

SEVERITY: Mild to moderate

LOCATION: US Only

View Details

Aviclear for Hidradenitis Suppurativa (HS)

AGE: 18-60

HURLEY STAGE: I & II

LOCATION: US Only

View Details

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

AGE: 18-70

HURLEY STAGE: II & III

LOCATION: US Only

View Details

Deucravacitinib Clinical Trial

AGE: 18-70

HURLEY STAGE: All

LOCATION: US Only

View Details

Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation

AGE: 18+

SEVERITY: Moderate to Severe

LOCATION: International

View Details

Clinical and Biological Characteristics of Hidradenitis Suppurativa

AGE: 13+

HURLEY STAGE: All

LOCATION: US Only

View Details

The Living With a Long-Term Condition Study

AGE: 18+

HURLEY STAGE: All

LOCATION: International

View Details

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: II & III

LOCATION: US Only

View Details

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

AGE: 18-70

HURLEY STAGE: II & III

LOCATION: International

View Details

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

AGE: 10+

HURLEY STAGE: All

LOCATION: US Only

View Details

Botulinum Toxin Therapy in Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

Regulation of Inflammatory Genes in Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

Myriad™ Augmented Soft Tissue Reconstruction Registry

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

HS Mindfulness Training Trial

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: II & III

LOCATION: US Only

View Details

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with Moderate to Severe Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: II & III

LOCATION: US Only

View Details

Anifrolumab Clinical Trial

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

AGE: 12+

HURLEY STAGE: I & II

LOCATION: US Only

View Details

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

AGE: 18+

SEVERITY: Moderate to Severe

LOCATION: US Only

View Details

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

AGE: 16+

HURLEY STAGE: II & III

LOCATION: International

View Details

Anifrolumab for Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

AGE: 18+

HURLEY STAGE: All

LOCATION: International

View Details

Battlefield Acupuncture for Pain in Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

AGE: 18+

HURLEY STAGE: All

LOCATION: International

View Details

Physical Activity Trial

AGE: 18-80

SEVERITY: Moderate to Severe

LOCATION: US Only

View Details

Patient’s Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

AGE: 18+

HURLEY STAGE: All

LOCATION: International

View Details

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

AGE: 18+

SEVERITY: Moderate to Severe

LOCATION: International

View Details

A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

AGE: 7+

HURLEY STAGE: All

LOCATION: International

View Details

HIDRAdenitis Suppurativa and HEART Disease

AGE: 18+

HURLEY STAGE: All

LOCATION: International

View Details

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

AGE: 18+

HURLEY STAGE: All

LOCATION: US Only

View Details

A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

AGE: 18-70

HURLEY STAGE: II & III

LOCATION: International

View Details

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

AGE: 18-70

HURLEY STAGE: II & III

LOCATION: US Only

View Details

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

AGE: 12+

HURLEY STAGE: II & III

LOCATION: International

View Details

The Ohio State University Dermatology Biorepository

AGE: 7+

HURLEY STAGE: All

LOCATION: US Only

View Details

Intralesional Diode Laser Treatment of Fistulas in Hidradenitis Suppurativa

AGE: 18+

HURLEY STAGE: All

LOCATION: International

View Details

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

AGE: 18+

SEVERITY: Moderate to Severe

LOCATION: International

View Details

Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa

AGE: 18-70

HURLEY STAGE: All

LOCATION: International

View Details

×